



Disposals of own shares

Brussels (Belgium), 24 July 2020 – 20:00 (CEST) – regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

| Date of transaction | Time | LTI Plan | Number of disposed UCB shares | Price |
|---------------------|----------|------------------------|-------------------------------|---------|
| 17 juli 2020 | 11:14:19 | Stock Option Plan 2013 | 100 | € 48.69 |
| 17 juli 2020 | 12:06:10 | Stock Option Plan 2012 | 100 | € 32.36 |
| 17 juli 2020 | 12:20:59 | Stock Option Plan 2014 | 1000 | € 58.12 |
| 17 juli 2020 | 13:16:56 | Stock Option Plan 2015 | 750 | € 67.35 |
| 17 juli 2020 | 13:19:59 | Stock Option Plan 2014 | 500 | € 58.12 |
| 17 juli 2020 | 13:45:32 | Stock Option Plan 2012 | 100 | € 32.36 |
| 17 juli 2020 | 14:00:43 | Stock Option Plan 2013 | 1000 | € 48.69 |
| 17 juli 2020 | 15:35:06 | Stock Option Plan 2013 | 100 | € 48.69 |
| 17 juli 2020 | 15:35:06 | Stock Option Plan 2013 | 500 | € 48.69 |
| 17 juli 2020 | 15:57:40 | Stock Option Plan 2011 | 500 | € 26.72 |
| 17 juli 2020 | 16:24:12 | Stock Option Plan 2014 | 500 | € 58.12 |
| 20 juli 2020 | 09:00:43 | Stock Option Plan 2014 | 1900 | € 58.12 |
| 20 juli 2020 | 15:30:58 | Stock Option Plan 2011 | 100 | € 26.72 |
| 21 juli 2020 | 12:46:40 | Stock Option Plan 2017 | 200 | € 70.26 |
| 21 juli 2020 | 14:11:00 | Stock Option Plan 2017 | 1800 | € 70.26 |
| 22 juli 2020 | 09:00:24 | Stock Option Plan 2012 | 3200 | € 32.36 |
| 23 juli 2020 | 16:15:37 | Stock Option Plan 2012 | 2,000 | € 32.36 |

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)